Search Results - "Gruenwald, V."

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies by Grünwald, V, Seidel, C, Fenner, M, Ganser, A, Busch, J, Weikert, S

“…Background: Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who…”
Get full text

LBA90 A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415) by Gruenwald, V.

Get full text

Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie by Knoedler, M, Gauler, T C, Gruenwald, V, Matzdorff, A, Schroeder, M, Dietz, A, Jordan, W-O, Arnold, D, Hennemann, B, Hofele, C, Weissinger, F, Eberhardt, W, Keilholz, U

“…Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated in…”
Get more information

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms by Rothermundt, C., von Rappard, J., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B., Schmidinger, M., Sternberg, C. N., Putora, P. M.

“…Background Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among…”
Get full text

Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival? by Ivanyi, P., Koenig, J., Trummer, A., Busch, J. F., Seidel, C., Reuter, C. W., Ganser, A., Grünwald, V.

“…Purpose To evaluate the impact of bone metastasis (BM) onset toward prognosis in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib…”
Get full text

Are we ready to accept intermediate outcome measures in clinical cancer trials? by Grünwald, V., Calvo, E.

Get full text

Long-term Survival After Cancer: A Scoping Review of the Health Care Landscape in Germany by Messer, S, Cryns, N, Ernst, M, Dirksen, U, Gruenwald, V, Skoetz, N

“…Abstract Background Cancer remains a global health concern, with a significant increase in new cases projected in the coming years. Although cancer treatment…”
Get full text

Combination hormone therapy for non-metastatic prostate cancer by Ohlmann, Carsten, Grünwald, V, Hadaschik, B

Get full text

804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC) by Albiges, L., Schmidinger, M., Taguieva-Pioger, N., Perol, D., Gruenwald, V.

Get full text

7138 The effect of zoledronic acid on bone metastasis in patients with metastatic renal cell cancer – a German prospective single-arm clinical trial by Gruenwald, V, Stenzl, A, Strauss, A, Kindler, M, Miller, K, Ruebel, A, Albrecht, M, Tunn, U

Get full text

681P OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117 by Gruenwald, V., Alt, J., Tometten, M., Haenel, M., Ivanyi, P., Schuch, G., Klinghammer, K., Gutsche, K., Hasenkamp, J., Hapke, G., Mänz, M., Weichert, W., Hahn, D.A.

Get full text

Sunitinib re-challenge in advanced renal-cell carcinoma by Porta, C, Paglino, C, Grünwald, V

“…Despite offering significant clinical benefits in advanced renal-cell carcinoma (RCC), the effectiveness of targeted therapies eventually declines with the…”
Get full text

912P Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115) by Gruenwald, V., Graeven, U., Ivanyi, P., Dietz, A., Hahn, D., Hackenberg, S., Kasper, S., Fietkau, R., Moulin, J-C., Pink, D., Schaaf, M., Klinghammer, K.

Get full text

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Powles, T, Albiges, L, Bex, A, Comperat, E, Grünwald, V, Kanesvaran, R, Kitamura, H, McKay, R, Porta, C, Procopio, G, Schmidinger, M, Suarez, C, Teoh, J, de Velasco, G, Young, M, Gillessen, S

Get more information

LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial by Motzer, R.J., Russo, P., Gruenwald, V., Tomita, Y., Zurawski, B., Parikh, O.A., Buti, S., Barthelemy, P., Goh, J.C.H., Ye, D., Lingua, A., Lattouf, J-B., Escudier, B., George, S., B. Shuch, Simsek, B., Spiridigliozzi, J., Chudnovsky, A., Bex, A.

Get full text

Molecular tumor board-renal cell carcinoma by Grünwald, V, Doehn, C, Goebell, P J

“…The introduction of molecular targeted agents has fundamentally changed the treatment of metastatic renal cell carcinoma. A first wave of development was based…”
Get full text

1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial by Gruenwald, V., McKay, R.R., Buchler, T., Eto, M., Park, S.H., Takagi, T., Zanetta, S., Keizman, D., Rodriguez, C. Suarez, Negrier, S., Lee, J-L., Santini, D., Bedke, J., Staehler, M., Kollmannsberger, C.K., Choueiri, T.K., Motzer, R.J., Burgents, J., Okpara, C.E., Powles, T.B.

Get full text

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma by Rini, B.I., Melichar, B., Fishman, M.N., Oya, M., Pithavala, Y.K., Chen, Y., Bair, A.H., Grünwald, V.

“…In a randomized, double-blind phase II trial in patients with metastatic renal cell carcinoma (mRCC), axitinib versus placebo titration yielded a significantly…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

“…Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and…”
Get full text

Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna by Perez-Gracia, J.L., Penel, N., Calvo, E., Arkenau, H.T., Amaral, T., Grünwald, V., Sanmamed, M.F.

Get full text